Literature DB >> 9013277

Correlation between pancreatic endocrine and exocrine function and characteristics of pancreatic endocrine function in patients with diabetes mellitus owing to chronic pancreatitis.

T Nakamura1, K Imamura, K Takebe, A Terada, Y Arai, Y Tandoh, N Yamada, M Ishii, K Machida, T Suda.   

Abstract

CONCLUSION: Pancreatic endocrine capacities are remarkably disturbed in patients with pancreatic diabetes owing to calcific pancreatitis as opposed to those owing to noncalcific pancreatitis. Insulin secretion in calcific pancreatitis resembled that in insulin-dependent diabetes mellitus (IDDM), whereas insulin secretion in noncalcific pancreatitis resembled that in non-IDDM (NIDDM). The involvements of acinar cell and ductal cell function closely correlate with endocrine function (insulin and glucagon secretions) in chronic pancreatitis (pancreatic diabetes).
BACKGROUND: We sought to clarify the differences of pancreatic endocrine function between pancreatic diabetes and primary diabetes, and to verify the correlations between pancreatic exocrine and endocrine dysfunction in patients with chronic pancreatitis.
METHODS: Urinary C-peptide (CPR) excretion and fasting plasma glucagon levels in patients with pancreatic diabetes owing to calcific pancreatitis (19 cases) and owing to noncalcific pancreatitis (14 cases) were studied in comparison with those in patients with insulin-dependent diabetes mellitus (IDDM, 23 cases), noninsulin-dependent diabetes (NIDDM, 18 cases), and in healthy controls (11 cases). In addition, pancreatic exocrine function was investigated in patients with chronic pancreatitis (calcific and noncalcific) and in healthy controls. The correlation between pancreatic exocrine and endocrine function was studied.
RESULTS: The urinary CPR excretion in controls was 94.9 +/- 20.5 micrograms/d. The urinary CPR excretion in calcific pancreatitis was 12.8 +/- 7.4 micrograms/d and it resembled that in IDDM (9.4 +/- 5.8 micrograms/d). The urinary CPR excretion in noncalcific pancreatitis was 41.5 +/- 30.1 micrograms/d, being similar to that in NIDDM (49.3 +/- 21.0 micrograms/d). The plasma glucagon level in calcific pancreatitis was 64.1 +/- 15.9 rho g/mL, which was significantly lower than the values in IDDM (111.2 +/- 50.2 rho g/mL) and NIDDM (96.7 +/- 21.9 rho g/mL). The plasma glucagon level in calcific and noncalcific pancreratitis (88.4 +/- 29.6 rho g/mL) were significantly lower than that in controls (129.8 +/- 21.6 rho g/mL). The residual capacities of acinar cells and ductal cells were strongly correlated with urinary CPR excretion and plasma glucagon concentration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9013277     DOI: 10.1007/bf02803765

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  29 in total

1.  Pancreozymin-secretin test. The combined study of serum enzymes and duodenal contents in the diagnosis of pancreatic disease.

Authors:  D C SUN; H SHAY
Journal:  Gastroenterology       Date:  1960-04       Impact factor: 22.682

Review 2.  Endoscopic retrograde cholangiopancreatography in chronic pancreatitis. Cambridge classification.

Authors:  A T Axon
Journal:  Radiol Clin North Am       Date:  1989-01       Impact factor: 2.303

3.  Exocrine and endocrine pancreatic function in diabetes mellitus and chronic pancreatitis.

Authors:  N Peters; A P Dick; C N Hales; D H Orrell; M Sarner
Journal:  Gut       Date:  1966-06       Impact factor: 23.059

4.  Pancreatic glucagon secretion and exocrine function (BT-PABA test) in chronic pancreatitis.

Authors:  U Keller; E Szöllösy; L Varga; K Gyr
Journal:  Dig Dis Sci       Date:  1984-09       Impact factor: 3.199

5.  Human C-peptide immunoreactivity (CPR) in blood and urine - evaluation of a radioimmunoassay method and its clinical applications.

Authors:  T Kuzuya; T Saito; S Yoshida; A Matsuda
Journal:  Diabetologia       Date:  1976-10       Impact factor: 10.122

6.  Glucagon immunoreactivities and amino acid profile in plasma of duodenopancreatectomized patients.

Authors:  W A Muller; M Berger; P Suter; H J Cüppers; J Reiter; T Wyss; P Berchtold; F H Schmidt; J P Assal; A E Renold
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

7.  Glucagon levels and ketogenesis in human diabetes following total or partial pancreatectomy and severe chronic pancreatitis.

Authors:  S Del Prato; F Riva; A Devidé; R Nosadini; D Fedele; A Tiengo
Journal:  Acta Diabetol Lat       Date:  1980 Apr-Jun

8.  B cell function in patients with chronic pancreatitis and its relation to exocrine pancreatic function.

Authors:  B Nyboe Andersen; T Krarup; N T Thorsgaard Pedersen; O K Faber; C Hagen; H Worning
Journal:  Diabetologia       Date:  1982-08       Impact factor: 10.122

Review 9.  Correlation of imaging and function in chronic pancreatitis.

Authors:  P Malfertheiner; M Büchler
Journal:  Radiol Clin North Am       Date:  1989-01       Impact factor: 2.303

10.  Glucose counterregulation in diabetes secondary to chronic pancreatitis.

Authors:  S Larsen; J Hilsted; E K Philipsen; B Tronier; N J Christensen; M Damkjaer Nielsen; H Worning
Journal:  Metabolism       Date:  1990-02       Impact factor: 8.694

View more
  10 in total

Review 1.  The early diagnosis of pancreatic cancer and diabetes: what's the relationship?

Authors:  Changsong Zhang; Guangshun Yang; Yang Ling; Guihua Chen; Tianbao Zhou
Journal:  J Gastrointest Oncol       Date:  2014-12

Review 2.  [Diagnosis and therapy of chronic pancreatitis].

Authors:  R Mahlke; H Lübbers; P G Lankisch
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

3.  The current managements of pancreatic diabetes in Japan.

Authors:  Ken Kawabe; Tetsuhide Ito; Hisato Igarashi; Ryoichi Takayanagi
Journal:  Clin J Gastroenterol       Date:  2009-01-07

4.  Effects of high-lipase pancreatin on fecal fat, neutral sterol, bile acid, and short-chain fatty acid excretion in patients with pancreatic insufficiency resulting from chronic pancreatitis.

Authors:  T Nakamura; Y Tandoh; A Terada; N Yamada; T Watanabe; A Kaji; K Imamura; H Kikuchi; T Suda
Journal:  Int J Pancreatol       Date:  1998-02

5.  High prevalence of steatorrhea in 101 diabetic patients likely to suffer from exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations: a prospective multicenter study.

Authors:  Philip D Hardt; Annette Hauenschild; Clemens Jaeger; Joachim Teichmann; Reinhard G Bretzel; Hans U Kloer
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

6.  Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan.

Authors:  Tetsuhide Ito; Makoto Otsuki; Takao Itoi; Tooru Shimosegawa; Akihiro Funakoshi; Keiko Shiratori; Satoru Naruse; Yoshikazu Kuroda
Journal:  J Gastroenterol       Date:  2007-04-26       Impact factor: 7.527

7.  Oxidative stress and antioxidant capacity in patients with chronic pancreatitis with and without diabetes mellitus.

Authors:  Namrata Singh; Payal Bhardwaj; Ravinder M Pandey; Anoop Saraya
Journal:  Indian J Gastroenterol       Date:  2012-08-25

Review 8.  New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer.

Authors:  Rahul Pannala; Ananda Basu; Gloria M Petersen; Suresh T Chari
Journal:  Lancet Oncol       Date:  2009-01       Impact factor: 41.316

9.  Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus.

Authors:  Rahul Pannala; Jeffery B Leirness; William R Bamlet; Ananda Basu; Gloria M Petersen; Suresh T Chari
Journal:  Gastroenterology       Date:  2008-01-18       Impact factor: 22.682

10.  Total cholesterol level for assessing pancreatic insufficiency due to chronic pancreatitis.

Authors:  Kenji Hirano; Tomotaka Saito; Suguru Mizuno; Minoru Tada; Naoki Sasahira; Hiroyuki Isayama; Miho Matsukawa; Gyotane Umefune; Dai Akiyama; Kei Saito; Shuhei Kawahata; Naminatsu Takahara; Rie Uchino; Tsuyoshi Hamada; Koji Miyabayashi; Dai Mohri; Takashi Sasaki; Hirofumi Kogure; Natsuyo Yamamoto; Yosuke Nakai; Kazuhiko Koike
Journal:  Gut Liver       Date:  2014-04-23       Impact factor: 4.519

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.